Prelude Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Prelude Therapeutics has a total shareholder equity of $156.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $197.2M and $40.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$153.63m |
| Equity | US$156.43m |
| Total liabilities | US$40.79m |
| Total assets | US$197.22m |
Recent financial health updates
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Sep 16
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 09Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Sep 17We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Jan 28We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
Oct 27Recent updates
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Sep 16We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 09Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Feb 03Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Sep 17We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
May 28Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
Jan 28We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
Oct 27Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Oct 18Prelude downgraded at Morgan Stanley ahead of key update
Sep 09We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Jun 28Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Mar 14We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
Dec 14Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Jul 05What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?
Feb 16
Prelude Therapeutics prices $150M share offering
Jan 07Prelude Therapeutics readies public offering
Jan 04Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares
Dec 25Financial Position Analysis
Short Term Liabilities: PRLD's short term assets ($156.4M) exceed its short term liabilities ($22.2M).
Long Term Liabilities: PRLD's short term assets ($156.4M) exceed its long term liabilities ($18.6M).
Debt to Equity History and Analysis
Debt Level: PRLD is debt free.
Reducing Debt: PRLD has no debt compared to 5 years ago when its debt to equity ratio was 1.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRLD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PRLD has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 25.4% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 20:42 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Prelude Therapeutics Incorporated is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Graig Suvannavejh | Goldman Sachs |